Q3 EPS Estimates for Oric Pharmaceuticals Reduced by Wedbush

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) – Wedbush dropped their Q3 2025 earnings per share estimates for Oric Pharmaceuticals in a research report issued to clients and investors on Tuesday, August 12th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings of ($0.38) per share for the quarter, down from their previous estimate of ($0.36). Wedbush has a “Outperform” rating and a $20.00 price objective on the stock. The consensus estimate for Oric Pharmaceuticals’ current full-year earnings is ($2.17) per share. Wedbush also issued estimates for Oric Pharmaceuticals’ Q4 2025 earnings at ($0.35) EPS, FY2025 earnings at ($1.60) EPS, FY2026 earnings at ($1.53) EPS, FY2027 earnings at ($1.68) EPS and FY2028 earnings at ($1.33) EPS.

Oric Pharmaceuticals (NASDAQ:ORIC) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.47) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($0.01).

A number of other brokerages have also recently commented on ORIC. Zacks Research raised Oric Pharmaceuticals to a “hold” rating in a research report on Tuesday. LADENBURG THALM/SH SH started coverage on Oric Pharmaceuticals in a research report on Tuesday, July 8th. They set a “buy” rating and a $15.00 price target on the stock. Oppenheimer dropped their price target on Oric Pharmaceuticals from $15.00 to $12.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 6th. JPMorgan Chase & Co. dropped their price target on Oric Pharmaceuticals from $20.00 to $17.00 and set an “overweight” rating on the stock in a research report on Thursday. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Oric Pharmaceuticals in a research report on Tuesday, May 6th. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat.com, Oric Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $17.63.

Oric Pharmaceuticals Trading Down 2.7%

ORIC stock opened at $9.66 on Friday. Oric Pharmaceuticals has a 1-year low of $3.90 and a 1-year high of $14.67. The stock’s fifty day simple moving average is $10.30 and its two-hundred day simple moving average is $8.10. The stock has a market cap of $938.18 million, a P/E ratio of -5.11 and a beta of 1.69.

Institutional Trading of Oric Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in ORIC. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Oric Pharmaceuticals by 2.9% in the 2nd quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 49,000 shares of the company’s stock worth $497,000 after acquiring an additional 1,358 shares during the last quarter. ANTIPODES PARTNERS Ltd increased its stake in Oric Pharmaceuticals by 35.9% in the 2nd quarter. ANTIPODES PARTNERS Ltd now owns 5,194 shares of the company’s stock worth $53,000 after acquiring an additional 1,372 shares during the last quarter. Invesco Ltd. increased its stake in Oric Pharmaceuticals by 8.5% in the 4th quarter. Invesco Ltd. now owns 23,958 shares of the company’s stock worth $193,000 after acquiring an additional 1,876 shares during the last quarter. Nisa Investment Advisors LLC increased its stake in Oric Pharmaceuticals by 17,300.0% in the 2nd quarter. Nisa Investment Advisors LLC now owns 2,436 shares of the company’s stock worth $25,000 after acquiring an additional 2,422 shares during the last quarter. Finally, Ameriprise Financial Inc. increased its stake in Oric Pharmaceuticals by 7.5% in the 2nd quarter. Ameriprise Financial Inc. now owns 38,864 shares of the company’s stock worth $394,000 after acquiring an additional 2,706 shares during the last quarter. Hedge funds and other institutional investors own 95.05% of the company’s stock.

Insider Transactions at Oric Pharmaceuticals

In related news, CFO Dominic Piscitelli sold 32,466 shares of the stock in a transaction dated Tuesday, June 24th. The stock was sold at an average price of $10.50, for a total transaction of $340,893.00. Following the sale, the chief financial officer owned 68,317 shares of the company’s stock, valued at approximately $717,328.50. This represents a 32.21% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Angie You acquired 26,597 shares of the company’s stock in a transaction that occurred on Friday, June 20th. The shares were bought at an average cost of $9.39 per share, for a total transaction of $249,745.83. Following the acquisition, the director directly owned 26,597 shares in the company, valued at $249,745.83. This represents a ∞ increase in their position. The disclosure for this purchase can be found here. Insiders have sold a total of 40,000 shares of company stock worth $416,289 in the last three months. 6.82% of the stock is currently owned by insiders.

About Oric Pharmaceuticals

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.